Native T1诊断与风险预测转甲状腺素蛋白淀粉样变心肌病
在2011-2025年国家淀粉样变转诊中心1675例疑诊或确诊ATTR患者队列中,分类为无症状TTR变异携带者、心外ATTR、早期ATTR-CM及显性ATTR-CM。研究定义native T1诊断阈值和风险分层,并与ECV比较诊断及预后表现。结果显示native T1随疾病阶段阶梯式升高,ECV校准的native T1风险分层可重现3年死亡率梯度。
要点
- native T1≤1050 ms可辅助排除心脏受累,灵敏度93%特异度84%。
- native T1≥1100 ms辅助识别显性ATTR-CM,灵敏度75%特异度88%。
- native T1分层可提供预后信息,但ECV在有对比剂CMR时仍为首选。
核心结论
- native T1可提供实用的诊断支持阈值,ECV校准的native T1分层可再现分级3年死亡风险。
- native T1提供无对比剂诊断与风险分层的实用方法,但可获取对比剂CMR时ECV仍是首选定量标志物。
- native T1阈值和z-score方法在推广至其他中心前仍需本地校准和外部验证。
研究设计与样本
- 观察性队列研究,纳入2011-2025年国家淀粉样变转诊中心1675例疑诊或确诊ATTR并行CMR的受试者。
- 受试者分为无症状TTR变异携带者125例、心外ATTR 44例、早期ATTR-CM 73例、显性ATTR-CM 1433例。
- 使用Cox模型分析全因死亡率,native T1分层以3年死亡率校准至预设的ECV分层。
关键影像表现/征象
- native T1值随疾病分类阶梯式升高,并与ECV相关(r=0.62),晚期疾病中耦合程度减弱。
诊断标准与关键数值
- native T1≤1050 ms(z-score +1.14)识别低心脏受累概率的灵敏度为93%,特异度为84%。
- native T1≥1100 ms(z-score +2.40)识别显性ATTR-CM的灵敏度为75%,特异度为88%。
- ECV校准的native T1风险分层重现3年死亡率阶梯式梯度,低至中等T1区梯度更陡,较高T1区相对平台化。
临床应用与阅片要点
- native T1≤1050 ms可用于门诊场景下低概率心脏受累筛查,减少不必要对比剂使用。
- native T1≥1100 ms提示显性ATTR-CM可能,需结合其他影像和临床证据综合判断。
- 加入native T1分层可在临床变量之外改善预后信息,可用于风险沟通与随访分层。
局限性
- native T1阈值和z-score方法仍需本地校准和外部验证后方可推广至其他中心。
- 研究为单一国家转诊中心队列,可能存在选择偏倚且阈值中心特异性尚不明确。
- 晚期疾病中native T1与ECV耦合减弱,提示native T1在疾病晚期定量价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Native T1 mapping is a contrast-free cardiac magnetic resonance (CMR) marker of myocardial amyloid infiltration, but center-specific diagnostic cutoffs and prognostic strata remain incompletely defined across transthyretin amyloidosis (ATTR).
OBJECTIVES: This study aims to define native T1 thresholds and risk strata across the ATTR spectrum and compare its diagnostic and prognostic performance with extracellular volume (ECV).
METHODS: In a cohort at a national referral amyloidosis center (2011-2025), 1,675 individuals undergoing CMR for suspected or confirmed ATTR were classified as asymptomatic TTR-variant carriers (n = 125), extracardiac ATTR (n = 44), early ATTR-CM (n = 73), or overt ATTR-CM (n = 1,433). Diagnostic targets were: 1) any cardiac involvement (early/overt ATTR-CM); and 2) overt vs early ATTR-CM. All-cause mortality from national records was analyzed with Cox models; native T1 strata were calibrated to predefined ECV strata using 3-year mortality.
RESULTS: Native T1 rose stepwise across disease categories and correlated with ECV (r = 0.62), with weaker coupling in advanced disease. Over a median 3.3 years, 822 of 1,675 (49%) participants died. Native T1 ≤1,050 ms (z-score +1.14) identified a low likelihood of cardiac involvement with 93% sensitivity and 84% specificity, whereas native T1 ≥1,100 ms (z-score +2.40) identified overt ATTR-CM with 75% sensitivity and 88% specificity. Calibration against ECV strata yielded native T1 risk categories that reproduced a stepwise 3-year mortality gradient, with a stronger gradient at low to intermediate T1 and relative plateauing at higher T1; adding native T1 strata improved prognostic information beyond clinical variables.
CONCLUSIONS: Native T1 can provide pragmatic diagnostic supportive thresholds, whereas ECV-calibrated native T1 strata reproduced a graded 3-year mortality risk. Native T1 offers a practical contrast-free approach to support diagnosis and risk stratification, although ECV remains the preferred quantitative marker when contrast CMR is available. Thresholds and z-score based approaches still require local recalibration and external validation before adoption at other centers.
引用
- Aimo, Sheikh, Kakhi, et al. Native T1 for Diagnosis and Risk Prediction in Amyloid Transthyretin Cardiomyopathy: An Observational Study on 1,675 Subjects. JACC Cardiovasc Imaging. 2026. PMID: 42799727. doi:10.1016/j.jcmg.2026.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。